Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23589806 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18878464 | 0.84 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25467701 | 0.84 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25467690 | 0.84 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23707575 | 0.82 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25876249 | 0.81 | DDB1 (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15502840 | 0.81 | DDB1 (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20317527 | 0.81 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL677366 | 0.81 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL17246852 | 0.81 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | DDB1 2095/4885CRBN 3656/4885IKZF3 3769/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | DDB1 1650/4885CRBN 500/4885IKZF3 2131/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | DDB1 985/4885CRBN 474/4885IKZF3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.